Short Interest in Menlo Therapeutics Inc (NASDAQ:MNLO) Rises By 44.1%

Menlo Therapeutics Inc (NASDAQ:MNLO) saw a significant growth in short interest in the month of June. As of June 30th, there was short interest totalling 109,800 shares, a growth of 44.1% from the May 30th total of 76,200 shares. Currently, 0.9% of the company’s shares are sold short. Based on an average daily trading volume, of 57,200 shares, the days-to-cover ratio is presently 1.9 days.

Shares of MNLO traded up $0.21 during trading hours on Friday, reaching $4.93. 56,000 shares of the company traded hands, compared to its average volume of 75,009. The stock has a fifty day moving average of $6.15. The stock has a market capitalization of $119.20 million, a price-to-earnings ratio of -2.08 and a beta of 2.47. Menlo Therapeutics has a 12-month low of $3.74 and a 12-month high of $12.00.

Menlo Therapeutics (NASDAQ:MNLO) last released its quarterly earnings data on Thursday, May 2nd. The company reported ($0.81) earnings per share for the quarter, meeting the consensus estimate of ($0.81). On average, equities analysts expect that Menlo Therapeutics will post -3.37 earnings per share for the current year.

Several hedge funds have recently added to or reduced their stakes in MNLO. Rhumbline Advisers bought a new stake in shares of Menlo Therapeutics in the fourth quarter valued at about $48,000. Bank of New York Mellon Corp raised its holdings in shares of Menlo Therapeutics by 51.0% in the fourth quarter. Bank of New York Mellon Corp now owns 38,662 shares of the company’s stock valued at $159,000 after acquiring an additional 13,064 shares in the last quarter. Bank of America Corp DE raised its holdings in shares of Menlo Therapeutics by 8.9% in the fourth quarter. Bank of America Corp DE now owns 42,160 shares of the company’s stock valued at $173,000 after acquiring an additional 3,448 shares in the last quarter. Acadian Asset Management LLC raised its holdings in shares of Menlo Therapeutics by 18.0% in the first quarter. Acadian Asset Management LLC now owns 42,314 shares of the company’s stock valued at $333,000 after acquiring an additional 6,459 shares in the last quarter. Finally, Geode Capital Management LLC raised its holdings in shares of Menlo Therapeutics by 4.5% in the fourth quarter. Geode Capital Management LLC now owns 84,387 shares of the company’s stock valued at $347,000 after acquiring an additional 3,608 shares in the last quarter. Hedge funds and other institutional investors own 73.95% of the company’s stock.

A number of analysts have recently issued reports on MNLO shares. Cantor Fitzgerald reissued a “buy” rating and set a $25.00 target price on shares of Menlo Therapeutics in a research note on Thursday, May 2nd. Zacks Investment Research raised shares of HB Fuller from a “sell” rating to a “hold” rating in a research note on Wednesday, July 3rd. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $17.00.

About Menlo Therapeutics

Menlo Therapeutics Inc, a late-stage biopharmaceutical company, focuses on the development and commercialization of serlopitant for the treatment of pruritus associated with dermatologic conditions in the United States. The company has completed Phase II clinical trials in pruritus associated with prurigo nodularis; psoriasis; chronic pruritus; atopic dermatitis; and refractory chronic cough.

Featured Story: How is a buy-side analyst different from a sell-side analyst?

Receive News & Ratings for Menlo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Menlo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.